Hepatitis/MASH

Researchers find cooperation among viral variants that help hepatitis C to survive.

Comprehensive screening guidelines needed for populations with multiple risk factors.

Marketplace users less likely to use most medication classes except for hepatitis C and HIV.

Therapy is also being evaluated for advanced chronic kidney disease, inherited blood disorders, and liver cirrhosis.

Predictive model uses routine lab values and machine learning method.

Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection.

Combination is now being considered for patients who received a liver transplant.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.

The FDA today amended its breakthrough therapy designation for an experimental hepatitis C drug combination.

Study finds benefits from reduced absenteeism and improved workplace productivity.

Height can impact wait times for transplantation and overall mortality.

Blood test predicts which patients will respond to interferon.

Promising results from generic formulation of drug used post-transplant to reduce the risk of organ rejection.

Investigational 3-drug combination cleared the virus in 93% of treatment-naïve patients.

Direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir showed high rates of sustained virologic response after 12 weeks.

Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.

HIV and HCV co-infected patients with HALS found to be more likely to develop cirrhosis.

Liver damage is the bane of HIV-infected patients' existence.

A look back at the top stories on Specialty Pharmacy Times from May 4 to May 8.

Cancer rates significantly greater compared with non-infected individuals.

Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.

Cirrhosis-related death rates drop across all age brackets.

Therapy shows promise in treatment of hepatitis C genotype-1 mono-infected patients.

Raplixa reduces time needed to stop bleeding during surgery.

Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.